Evidence map›Paper›PMID 40208862›Full record

ArticlePLoS biology2025

Modulation of NMDA receptor signaling and zinc chelation prevent seizure-like events in a zebrafish model of SLC13A5 epilepsy.

Deepika Dogra, Van Anh Phan, Sinan Zhang, Cezar Gavrilovici, Nadia DiMarzo, Ankita Narang, Kingsley Ibhazehiebo, Deborah M Kurrasch

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deepika DograDepartment of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
Van Anh PhanDepartment of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
Sinan ZhangDepartment of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
Cezar GavriloviciDepartment of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
Nadia DiMarzoDepartment of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
Ankita NarangAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
Kingsley IbhazehieboDepartment of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
Deborah M KurraschDepartment of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-9945-287X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SLC13A5 encodes a citrate transporter highly expressed in the brain and is important for regulating intra- and extracellular citrate levels. Mutations in this gene cause rare infantile epilepsy characterized by lifelong seizures, developmental delays, behavioral deficits, poor motor progression, and language impairments. SLC13A5 individuals respond poorly to treatment options; yet drug discovery programs are limited due to a paucity of animal models that phenocopy human symptoms. Here, we used CRISPR/Cas9 to create loss-of-function mutations in slc13a5a and slc13a5b, the zebrafish paralogs to human SLC13A5. slc13a5 mutant larvae showed cognitive dysfunction and sleep disturbances, consistent with SLC13A5 individuals. These mutants also exhibited fewer neurons and a concomitant increase in apoptosis across the optic tectum, a region important for sensory processing. Further, slc13a5 mutants displayed hallmark features of epilepsy, including an imbalance in glutamatergic and GABAergic excitatory-inhibitory gene expression, increased fosab expression, disrupted neurometabolism, and neuronal hyperexcitation as measured in vivo by extracellular field recordings and live calcium imaging. Mechanistically, we tested the involvement of NMDA signaling and zinc chelation in slc13a5 mutant epilepsy-like phenotypes. Slc13a5 protein co-localizes with excitatory NMDA receptors in wild-type zebrafish and NMDA receptor expression is upregulated in the brain of slc13a5 mutant larvae. Additionally, low levels of zinc are found in the plasma membrane of slc13a5 mutants. NMDA receptor suppression and ZnCl2 treatment in slc13a5 mutant larvae rescued neurometabolic and hyperexcitable calcium events, as well as behavioral defects. These data provide empirical evidence in support of the hypothesis that excess extracellular citrate over-chelates the zinc ions needed to regulate NMDA receptor function, leading to sustained channel opening and an exaggerated excitatory response that manifests as seizures. These data show the utility of slc13a5 mutant zebrafish for studying SLC13A5 epilepsy and open new avenues for drug discovery.

Indexed as

EpilepsyReceptors, N-Methyl-D-AspartateSeizuresSymportersZebrafish ProteinsZincAnimalsChelating AgentsDisease Models, AnimalHumansLarvaNeuronsSignal TransductionZebrafishChelating AgentsReceptors, N-Methyl-D-AspartateSymportersZebrafish ProteinsZinc

Identifiers

PMID40208862
PMCPMC12047791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.